NCT05177068 2025-10-02
Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer
Henan Cancer Hospital
Phase 2 Active not recruiting
Clinical Trials
4 trialsNCT06329973 2025-07-17
Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer
Henan Cancer Hospital
Phase 1/2 Recruiting
NCT06774222 2025-01-14
A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG
Henan Cancer Hospital
Phase 2 Recruiting
NCT06218888 2024-01-23
A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases
Fujian Cancer Hospital
Phase 2 Not yet recruiting